PetVivo Holdings, Inc. (PETV) stock
PETVOTCSurgical & Medical Instruments & ApparatusFiscal year ends March 31
$0.75+0.00 (0.00%)
Close on Oct 19, 2026Market cap $27.79MP/E –Yield –
PetVivo r&d expenses
Research and development expenses are spending on new products and technology.
PetVivo's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.31M, down 14.9% year over year. For fiscal 2026 it was $1.42M, down 10.6% from the year before. Over ten years it grew 23.7% a year on average. The highest annual figure on record is $1.58M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $1.42M | -10.6% |
| FY2025 | Mar 31, 2025 | $1.58M | +13.5% |
| FY2024 | Mar 31, 2024 | $1.40M | +40.0% |
| FY2023 | Mar 31, 2023 | $996.36K | +109.8% |
| FY2022 | Mar 31, 2022 | $474.88K | +383.4% |
| FY2021 | Mar 31, 2021 | $98.23K | +675.2% |
| FY2020 | Mar 31, 2020 | $12.67K | -93.7% |
| FY2019 | Mar 31, 2019 | $200.98K | +69.0% |
| FY2018 | Mar 31, 2018 | $118.94K | -29.2% |
| FY2017 | Mar 31, 2017 | $167.89K | -0.4% |
| FY2016 | Mar 31, 2016 | $168.60K | +3735.3% |
| FY2015 | Mar 31, 2015 | $4.40K | – |
| FY2012 | Mar 31, 2012 | $0 | -100.0% |
| FY2011 | Mar 31, 2011 | $157.30K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $233.42K | -31.5% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $490.10K | +36.7% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $322.99K | -13.2% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $261.43K | -43.8% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $340.51K | -12.1% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $358.61K | -8.2% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $371.95K | +5.8% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $465.17K | +29.5% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $387.52K | +31.9% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $390.59K | -27.2% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $351.58K | +41.7% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $359.33K | +156.0% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $293.77K | +310.0% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $536.16K | +186.4% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $248.16K | +622.9% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $140.38K | +20.6% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $71.66K | -47.7% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $187.24K | +175.5% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $34.33K | +13.4% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $116.38K | +14975.1% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $136.94K | +2772.0% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $67.97K | +853.0% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $30.27K | -55.0% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $772 | -98.6% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $4.77K | -93.9% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $7.13K | -87.3% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $67.19K | +303.3% |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $55.92K | +150.8% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $77.87K | +226.3% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $56.12K | +10.8% |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $16.66K | -60.5% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $22.29K | -67.9% |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $23.87K | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | $50.66K | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $42.19K | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | $69.55K | – |
See a number that looks wrong?